Global Sarcopenia Treatment Market, By Treatment Type (Medications, Vitamin/Dietary Supplements, and Others), Type (Primary Sarcopenia and Secondary Sarcopenia), Stages (Pre-Sarcopenia, Sarcopenia, and Severe Sarcopenia), Route of Administration (Oral, Injectable, and Others), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2030.
Sarcopenia Treatment Market Analysis and Size
The primary factors driving the growth of the global sarcopenia treatment market is the rising prevalence of sarcopenia. In addition, growing awareness of sarcoepnia and its detrimental effect on health is another key driver for market growth. Lifestyle factors such as poor nutrition and sedentary behavior also influence the market. However, the lack of standardized diagnosis and the high cost of treatment and intervention are expected to restrain market growth.
Data Bridge Market Research analyzes that the global sarcopenia treatment market is expected to reach the value of USD 4,043,993.94 thousand by 2030, at a CAGR of 4.9% during the forecast period 2023-2030. This market report also covers pricing analysis and technological advancements in depth.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Thousand
|
|
Segments Covered
|
Treatment Type (Medications, Vitamin/Dietary Supplements, and Others), Type (Primary Sarcopenia and Secondary Sarcopenia), Stages (Pre-Sarcopenia, Sarcopenia, and Severe Sarcopenia), Route of Administration (Oral, Injectable, and Others), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Denmark, Norway, Sweden, Poland, Finland and Rest of Europe, China, Japan, Australia, India, South Korea, New Zealand, Singapore, Thailand, Malaysia, Vietnam, Taiwan, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Bahrain, Qatar, Oman and Rest of Middle East and Africa
|
|
Market Players Covered
|
Abbott, Nestlé Health Science (A subsidiary of Nestlé S.A.), Novartis AG, Sanofi, Haleon Group of Companies. BASF SE, DSM, Fermenta Biotech Limited, AstaReal Co., Ltd., Metagenics, BioThrive Sciences., Wellona Pharma, The Vitamin Company India, Biogen SA , Healing Pharma India Pvt. Ltd., and among others
|
Market Definition
Sarcopenia treatment refers to the commercial landscape related to products and services aimed at preventing, managing, or addressing sarcopenia—a progressive age-related condition characterized by the loss of skeletal muscle mass, strength, and function, typically beginning around the age of 30 and accelerating after the age of 60. Sarcopenia has significant consequences on an individual's overall health and quality of life. There is a corresponding decline in muscle strength and endurance, making everyday tasks more challenging and increasing the risk of falls and fractures as muscle mass decreases. In addition, sarcopenia can lead to metabolic changes, insulin resistance, and an increased likelihood of obesity.
Global Sarcopenia Treatment Market Dynamics
Drivers
- Rising Prevalence of Sarcopenia
Sarcopenia is a medical condition characterized by the loss of muscle mass, strength, and function, particularly in older adults. They naturally experience a gradual loss of muscle mass and function, which predisposes them to sarcopenia as people age. The number of individuals at risk of developing sarcopenia is increasing steadily with the world's population aging. This demographic shift directly drives the demand for sarcopenia treatment options. The increasing prevalence of the condition means that more individuals require diagnosis and treatment, creating a larger patient pool for the global sarcopenia treatment market.
People are living longer lives with advances in healthcare and medicine. However, as individuals age, they are more likely to develop sarcopenia. This longer life expectancy contributes to the overall prevalence of the condition. Chronic illnesses such as diabetes, cardiovascular disease, and cancer can lead to muscle loss and contribute to the development of sarcopenia. The increasing incidence of these conditions has a direct impact on the rising prevalence of sarcopenia.
- Growing Awareness of Sarcopenia and its Detrimental Effects on Health
The growing awareness of sarcopenia and its detrimental effects on health is a significant development in the field of healthcare and aging. There has been a significant increase in research and publications related to sarcopenia. Scientific studies, medical journals, and publications have provided healthcare professionals with valuable information about the condition's prevalence, diagnosis, and consequences. Medical schools and training programs have incorporated sarcopenia into their curricula. This ensures that healthcare professionals, including doctors, nurses, and physical therapists, receive education about sarcopenia, its risk factors, and management strategies.
Various advocacy groups and organizations have been actively promoting awareness about sarcopenia. These groups often collaborate with healthcare professionals to educate the public about the conditions risks and the importance of early diagnosis and intervention. Sarcopenia has received increased coverage in mainstream media, including articles, news reports, and documentaries. This exposure has helped raise awareness among the general public.
Opportunity
- Strategic Initiatives by Market Players
The global sarcopenia treatment market is witnessing substantial growth as it is a progressive age-related condition characterized by the loss of muscle mass, strength, and function. It is a significant health concern, particularly among the elderly population, as it can lead to decreased mobility, increased risk of falls and fractures, and a decline in overall quality of life due to which key market players are proactively taking strategic initiatives for product development. Thus, opening up opportunities for market expansion and advancement.
Strategic initiative includes collaborations and partnerships with research institutions, healthcare organizations, and academic centers. Market players can leverage their knowledge and resources to accelerate the development and commercialization of sarcopenia treatments by collaborating with experts in the field. Such collaborations facilitate knowledge exchange, access to patient populations for clinical trials, and the pooling of expertise to drive innovation in the market.
Restraint / Challenge
- Lack of Standardized Diagnosis
Healthcare professionals may not routinely screen for the condition, especially in adults, which can hinder early intervention and treatment initiation. Without a standardized diagnosis, healthcare providers may use different criteria and methods to identify sarcopenia. This inconsistency can lead to variations in the reported prevalence of sarcopenia and the number of diagnosed cases, making it challenging to assess the true market size and demand for treatments.
Sarcopenia is a multifaceted condition that can affect individuals differently based on factors such as age, gender, and comorbidities. Patient groups may be heterogeneous, making it challenging to conduct clinical trials and research to evaluate treatment efficacy accurately without standardized diagnostic criteria. Clinical trials for sarcopenia treatments may use different diagnostic criteria, making it challenging to compare the results of various studies. This lack of standardization can hinder the development and approval of new treatments by regulatory agencies.
Global Sarcopenia Treatment Market Scope
The global sarcopenia treatment market is segmented into seven notable segments based on treatment type, type, stages, route of administration, gender, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Medications
- Vitamin/Dietary Supplements
- Others
On the basis of treatnent type, the market is segmented into vitamin/dietary supplements, medications, and others.
Type
- Primary Sarcopenia
- Secondary Sarcopenia
On the basis of type, the market is segmented into primary sarcopenia and secondary sarcopenia.
Stages
- Pre-Sarcopenia
- Sarcopenia
- Severe Sarcopenia
On the basis of stages, the market is segmented into pre-sarcopenia, sarcopenia, and severe sarcopenia.
Route of Administration
- Oral
- Injectable
- Others
On the basis of route of administration, the market is segmented into oral, injectable, and others.
Gender
- Male
- Female
On the basis of gender, the market is segmented into male and female.
End User
- Hospitals
- Home Healthcare
- Specialty Clinics
- Others
On the basis of end user, the market is segmented into hospitals, home healthcare, specialty clinics, and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
On the basis of distribution channel, the market is segmented into direct tenders, retail sales, and others.
Global Sarcopenia Treatment Market Regional Analysis/Insights
The global sarcopenia treatment market is segmented into seven notable segments based on treatment type, type, stages, route of administration, gender, end user, and distribution channel.
The countries covered in this global sarcopenia treatment market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Denmark, Norway, Sweden, Poland, Finland and Rest of Europe, China, Japan, Australia, India, South Korea, New Zealand, Singapore, Thailand, Malaysia, Vietnam, Taiwan, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Bahrain, Qatar, Oman and Rest of Middle East and Africa.
North America is dominating the global sarcopenia treatment market with the largest market share due to growing awareness and screening and rising healthcare expenditure. U.S. is the dominating country in North America region. Germany is dominating in Europe due to rising prevalence of cancer, and penetration of new technological advancements. Japan is dominating in Asia-Pacific due to to rising R & D activities and patient inclination towards personalized treatment.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Sarcopenia Treatment Market Share Analysis
The global sarcopenia treatment market competitive landscape provides details of the competitor. Details included are company overview, company financials, revenue generated, market potential, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major market players operating in the global sarcopenia treatment market are Abbott, Nestlé Health Science (A subsidiary of Nestlé S.A.), Novartis AG, Sanofi, Haleon Group of Companies. BASF SE, DSM, Fermenta Biotech Limited, AstaReal Co., Ltd., Metagenics, BioThrive Sciences., Wellona Pharma, The Vitamin Company India, Biogen SA , Healing Pharma India Pvt. Ltd., and among others.
SKU-